Catalog Number 112016 |
Device Problem
Fluid/Blood Leak (1250)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Type
malfunction
|
Manufacturer Narrative
|
Oxiris has been temporarily approved for use in the us under emergency use authorization eua(b)(4) with a specific indication to treat patients with covid-19 infection.Should additional relevant information become available, a supplemental report will be submitted.
|
|
Event Description
|
It was reported that an external fluid leak was observed from the ¿filter connection and the return line¿ of two (2) prismaflex oxiris sets at the start of continuous renal replacement therapy.A third set was used to continue treatment.There was no report of patient injury or medical intervention associated with this event.No additional information is available.
|
|
Manufacturer Narrative
|
Additional information added to d9, h3, h6 and h11: h11: one (1) device was received for evaluation.Visual inspection was performed and the set showed that the return screwed connector is damaged.An air leak test was performed and a leak was observed at the level of the return screwed connector due to a crack on the screwed connector.The reported condition was verified.The most probable cause of the damage is that a shock occurred during shipping or storage.A batch review was conducted and there were no deviations found related to this reported condition during the manufacture of this lot.Should additional relevant information become available, a supplemental report will be submitted.
|
|
Search Alerts/Recalls
|